Neuroimaging in Neurocysticercosis Clinical Presentation
- Author: Arturo Carpio, MD; Chief Editor: Niranjan N Singh, MD, DM more...
Neurocysticercosis (NC) is frequently asymptomatic. Cysticercosis of other tissues is almost always asymptomatic.
Clinical manifestations of NC are variable and dependent on the number and location of cysts as well as the host-immune response to the parasite.
The most frequent clinical manifestations are the following:
Focal neurological deficits
A myriad of syndromes have been described, including brainstem dysfunction, cerebellar ataxia, sensory deficits, involuntary movements, stroke, dementia, and hydrocephalus.
A survey carried out in Mexico on 205 patients with NC (114 adults and 92 children younger than age 15 y) who were diagnosed by means of neuroimaging reported that seizures were more frequent in children (80% vs 56%), while headache was more frequent in the adults (27% vs 15%).
Ten percent of patients present with ventricular cysts, with seizures, or with meningeal inflammation.
Symptoms include nausea, vomiting, headache, ataxia, and confusion.
Most of these clinical manifestations develop over a period of a few days, weeks, or months, with periods of remission and relapse, probably due to different evolutionary stages of the parasite.
No pathognomonic physical findings unmistakably identify a patient with NC. Virtually any neurological sign or symptom can occur, depending on the CNS location of the parasite.
Patients with cysts in the basal cisterns can present with meningeal signs, hydrocephalus, vasculitis, and stroke.
Cysticercal encephalitis with multiple parenchymal cysts (ie, associated inflammatory response, diffuse cerebral edema) is a rare presentation often seen in young girls. These patients are at a risk of developing severe neurological sequelae.
In patients with seizures, SECTL or hyperintense lesions on MRI are a common finding. The lesion is usually small, about 5-10 mm, well defined, annular or nodular, contrast enhancing, cortical or subcortical, and generally associated with perilesional edema and minimal mass effect, but without midline shift (see the image below). These patients, mainly children and young adults, have some benign and transitory clinical manifestations, predominantly partial or partial secondary generalized seizures, and occasionally Todd paresis or focal neurological deficits.
Risk factors associated with the disease include the following:
Immigration from areas of endemic disease
Family history of parasitic infestation
Household visitors from an endemic area
History of travel to an endemic area
Other diagnostic considerations include the following:
Focal signs may occur abruptly in patients who develop a cerebral infarction as a complication of subarachnoid NC.
Some manifestations of spinal NC are nonspecific, and the differential diagnosis with other diseases of the spinal cord is difficult on clinical grounds.
Arachnoiditis is characterized by root pain and weakness of subacute onset. Cysts in the spinal cord parenchyma usually occur with motor and sensory deficits that vary according to the level of the lesion.
Diffuse muscle involvement may result in a pseudohypertrophic myopathy. Patients have diffuse swelling of the muscles mimicking hypertrophy, myalgia, and muscle weakness.
Nash TE, Garcia HH. Diagnosis and treatment of neurocysticercosis. Nat Rev Neurol. 2011 Sep 13. 7(10):584-94. [Medline].
Del Brutto OH. Neurocysticercosis. Handb Clin Neurol. 2014. 121:1445-59. [Medline].
Roy B, Verma S, Awasthi R, Rathore RK, Venkatesan R, Yoganathan SA, et al. Correlation of phase values with CT Hounsfield and R2* values in calcified neurocysticercosis. J Magn Reson Imaging. 2011 Nov. 34(5):1060-4. [Medline].
Saenz B, Ruiz-Garcia M, Jimenez E, Hernandez-Aguilar J, Suastegui R, Larralde C. Neurocysticercosis: clinical, radiologic, and inflammatory differences between children and adults. Pediatr Infect Dis J. 2006 Sep. 25(9):801-3. [Medline].
Shrestha B, Mainali P, Sayami S, Shrestha OK. Clinico-radiological Aspects of Neurocysticercosis in Pediatric Population in a Tertiary Hospital. JNMA J Nepal Med Assoc. 2013 Jul-Sep. 52(191):483-8. [Medline].
Hernández RD, Durán BB, Lujambio PS. Magnetic resonance imaging in neurocysticercosis. Top Magn Reson Imaging. 2014 Jun. 23(3):191-8. [Medline].
Das K, Mondal GP, Banerjee M, Mukherjee BB, Singh OP. Role of antiparasitic therapy for seizures and resolution of lesions in neurocysticercosis patients: an 8 year randomised study. J Clin Neurosci. 2007 Dec. 14(12):1172-7. [Medline].
Gogia S, Talukdar B, Choudhury V, Arora BS. Neurocysticercosis in children: clinical findings and response to albendazole therapy in a randomized, double-blind, placebo-controlled trial in newly diagnosed cases. Trans R Soc Trop Med Hyg. 2003 Jul-Aug. 97(4):416-21. [Medline].
Del Brutto OH, Roos KL, Coffey CS, García HH. Meta-analysis: Cysticidal drugs for neurocysticercosis: albendazole and praziquantel. Ann Intern Med. 2006 Jul 4. 145(1):43-51. [Medline].
Garcia HH, Pretell EJ, Gilman RH, Martinez SM, Moulton LH, Del Brutto OH. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N Engl J Med. 2004 Jan 15. 350(3):249-58. [Medline].
Carpio A, Kelvin EA, Bagiella E, Leslie D, Leon P, Andrews H. Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry. 2008 Sep. 79(9):1050-5. [Medline].
Caplan LR. How to manage patients with neurocysticercosis. Eur Neurol. 1997. 37(2):124. [Medline].
Carpio A. Neurocysticercosis: an update. Lancet Infect Dis. 2002 Dec. 2(12):751-62. [Medline].
Carpio A, Escobar A, Hauser WA. Cysticercosis and epilepsy: a critical review. Epilepsia. 1998 Oct. 39(10):1025-40. [Medline].
Carpio A, Hauser WA. Prognosis for seizure recurrence in patients with newly diagnosed neurocysticercosis. Neurology. 2002 Dec 10. 59(11):1730-4. [Medline].
Carpio A, Hauser WA. Neurocysticercosis and epilepsy. Singh G, Prabhakar S, eds. Taenia Solium Cysticercosis. Oxon, UK: CABI Publishing; 2002. 211-20.
Carpio A, Placencia M, Santillan F. A proposal for classification of neurocysticercosis. Can J Neurol Sci. 1994 Feb. 21(1):43-7. [Medline].
Carpio A, Santillan F, Leon P. Is the course of neurocysticercosis modified by treatment with antihelminthic agents?. Arch Intern Med. 1995 Oct 9. 155(18):1982-8. [Medline].
Correa D, Medina-Escutia, E. Host-parasite immune relationship in Taenia solium taeniosis and cysticercosis. Garcia HH, Martinez, SM eds. Taenia solium Taeniasis/Cysticercosis. 1999. 15-24.
Davis L. Neurocysticercosis and seizures: Avoiding the cost of antihelminthic treatment. Neurology. 2002. 59:1669-71.
Dixon HBF, Lipscomb FM. Cysticercosis: an analysis and follow up of 450 cases. Med Res Council Special Reports. 1961. 299:1-58.
Escobar A. The pathology of neurocysticercosis. Cysticercosis of Central Nervous System. 1983:27-54.
Estanol B, Corona T, Abad P. A prognostic classification of cerebral cysticercosis: therapeutic implications. J Neurol Neurosurg Psychiatry. 1986 Oct. 49(10):1131-4. [Medline].
Flisser A, Correa D, Evans CAW. Taenia solium cysticercosis: New revisited immunological aspects. Singh G, Prabhakar S, eds. Taenia Solium Cysticercosis. Oxon, UK: CABI Publish; 2002. 24-44.
Garcia HH, Martinez M, Gilman R. Diagnosis of cysticercosis in endemic regions. The Cysticercosis Working Group in Peru. Lancet. 1991 Aug 31. 338(8766):549-51. [Medline].
Garg K, Singh K, Misra S. Single-enhancing lesions in Indians patients with seizures: a review. Epilepsy Res. 2002. 59:1730-1734.
Garg RK, Kar AM, Jain S. Failure of albendazole therapy in two common types of parenchymal neurocysticercosis. J Assoc Physicians India. 1995 Oct. 43(10):706-7. [Medline].
Goodman KA, Ballagh SA, Carpio A. Case-control study of seropositivity for cysticercosis in Cuenca, Ecuador. Am J Trop Med Hyg. 1999 Jan. 60(1):70-4. [Medline].
Kramer LD. Medical treatment of cysticercosis--ineffective. Arch Neurol. 1995 Jan. 52(1):101-2. [Medline].
Kramer LD, Locke GE, Byrd SE. Cerebral cysticercosis: documentation of natural history with CT [published erratum appears in Radiology 1989 Oct;173(1):286]. Radiology. 1989 May. 171(2):459-62. [Medline].
Manreza ML. Neurocysticercosis in children. Trends in Pediatric Neurology. 1993. 295-8.
Martinez HR, Rangel-Guerra R, Arredondo-Estrada JH. Medical and surgical treatment in neurocysticercosis a magnetic resonance study of 161 cases. J Neurol Sci. 1995 May. 130(1):25-34. [Medline].
McCormick GF, Zee CS, Heiden J. Cysticercosis cerebri. Review of 127 cases. Arch Neurol. 1982 Sep. 39(9):534-9. [Medline].
Mitchell WG, Crawford TO. Intraparenchymal cerebral cysticercosis in children: diagnosis and treatment. Pediatrics. 1988 Jul. 82(1):76-82. [Medline].
Padma MV, Behari M, Misra NK. Albendazole in single CT ring lesions in epilepsy. Neurology. 1994 Jul. 44(7):1344-6. [Medline].
Pal DK, Carpio A, Sander JW. Neurocysticercosis and epilepsy in developing countries. J Neurol Neurosurg Psychiatry. 2000 Feb. 68(2):137-43. [Medline].
Ramos-Kuri M, Montoya RM, Padilla A. Immunodiagnosis of neurocysticercosis. Disappointing performance of serology (enzyme-linked immunosorbent assay) in an unbiased sample of neurological patients. Arch Neurol. 1992 Jun. 49(6):633-6. [Medline].
Schantz PM. Cysticercosis in non-endemic countries: the example of United States. Teniasis/Cysticercosis por T. solium. 1996. 277-86.
Singhal BS, Salinas RA. Controversies in the Drug Treatment of Neurocysticercosis. Singh G, Prabhakar S, eds. Taenia Solium Cysticercosis. Oxon, UK: CABI Publish; 2002. 713-43.
Suss RA, Maravilla KR, Thompson J. MR imaging of intracranial cysticercosis: comparison with CT and anatomopathologic features. AJNR Am J Neuroradiol. 1986 Mar-Apr. 7(2):235-42. [Medline].
Teitelbaum GP, Otto RJ, Watanabe AT. MR imaging of neurocysticercosis. AJNR. 1989. 10:709-18.
Tsang VC, Brand JA, Boyer AE. An enzyme-linked immunoelectrotransfer blot assay and glycoprotein antigens for diagnosing human cysticercosis (Taenia solium). J Infect Dis. 1989 Jan. 159(1):100-2. [Medline].
White AC, Garcia HH. Recent Developments in the Epidemiology, Diagnosis, Treatment, and Prevention of Neurocysticercosis. Curr Infect Dis Rep. 1999 Dec. 1(5):434-440. [Medline].
Xiao ZX, Zhao CY, Liu YP. [Albendazole treatment in cerebral cysticercosis]. Chung Hua Nei Ko Tsa Chih. 1986 Feb. 25(2):100-2, 127. [Medline].
Zee CS, Segall HD, Destian S. MRI of intraventricular cysticercosis: surgical implications. J Comput Assist Tomogr. 1993 Nov-Dec. 17(6):932-9. [Medline].